Europe Benign Prostatic Hyperplasic Devices Market

The benign prostatic hyperplasic devices market in Europe is expected to grow from US$ 648.39 million in 2022 to US$ 994.84 million by 2028; it is estimated to grow at a CAGR of 7.4% from 2022 to 2028.

Players operating in the benign prostatic hyperplasic devices industry focus on investing high amounts in the development of advanced surgical technologies as alternatives to conventional techniques. Advanced devices enabled with new technologies help provide immediate relief and reduce morbidity. In January 2022, ProVerum, an Irish start-up supported by EIT Health, received US$ 31.22 million in Series A funding from Gilde Healthcare, Lightstone Ventures, and Atlantic Bridge. ProVerum has developed ProVee, a cutting-edge treatment solution for men with symptomatic BPH, and it aims to market its innovative device in Europe with the help of recent funding. Further, in June 2021, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by BPH or enlarged prostate, declared the completion of its Series B funding round with a total of US$ 24 million. The investment was led by Invus Opportunities and included participation from Medical Technology Venture Partners, F-Prime Capital, CloudStone Capital, Astia Angels, Golden Seeds, SV Tech Ventures, etc. In June 2021, Procept Biorobotics raised US$ 85 million to commercialize the AquaBeam system as a global BPH treatment. With this product, the company intends to make an impact with its water-based robotic technology in the field of prostate surgery. The series G financing was led by Fidelity Management & Research Company, with additional backing from T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office. The rise in such investments, funds, and grants for research in the field of BPH treatments is bolstering the benign prostatic hyperplasic devices market growth.

Europe Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million) 

Europe Benign Prostatic Hyperplasic Devices Strategic Insights

Strategic insights for the Europe Benign Prostatic Hyperplasic Devices provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Benign Prostatic Hyperplasic Devices Report Scope

Europe Benign Prostatic Hyperplasic Devices Regional Insights

The geographic scope of the Europe Benign Prostatic Hyperplasic Devices refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Benign Prostatic Hyperplasic Devices Market Segmentation

The Europe benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the Europe benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the Europe benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the Europe benign prostatic hyperplasic devices market is segmented into U.K., Germany, France, Italy, Spain, and Rest of Europe. In 2022, Germany held a larger market share. On the other side, and it is also expected to register a higher CAGR during the forecast period.

KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Europe benign prostatic hyperplasic devices market.